Jan 8, 2014 by Brian Orelli, PhDWhy Pharmacyclics and J&J's Lack of Data Is So AmazingPharmacyclics and Johnson & Johnson's Imbruvica beat GlaxoSmithKline's Arzerra in a head-to-head trial. But by how much?
Jan 7, 2014 by Brian Orelli, PhDNeurocrine Biosciences Inc. Nearly Doubles (but Not Really)Neurocrine Biosciences isn't up nearly as much as it appears.
Dec 31, 2013 by Brian Orelli, PhDGeron's Effortless Triple in 2013To keep the stock price growing, Geron will have to do some of its own work in 2014.
Dec 31, 2013 by Brian Orelli, PhDTop 3 FDA Approvals of 2013Drugs from Biogen Idec, Isis Pharmaceuticals, Johnson & Johnson, and Gilead top the charts.
Dec 31, 2013 by Brian Orelli, PhD3 Drugs That Increased Their Potential in 2013With a little help from the Food and Drug Administration, drugs from Celgene, VIVUS, and Theravance have a new life.
Dec 30, 2013 by Brian Orelli, PhDThe President Gets a Taste of His Own Obamacare MedicineOnly Obama-like enrollees can save Obamacare.
Dec 30, 2013 by Brian Orelli, PhDFDA Rejects Sanofi's MS Drug LemtradaDrug was key to Sanofi's purchase of Genzyme.
Dec 28, 2013 by Brian Orelli, PhDTop Health-Care Stocks for 2014Johnson & Johnson, Orexigen, and Geron have to potential to be top health-care stocks in 2014.
Dec 26, 2013 by Brian Orelli, PhDA Not-So Fat 2013 for This Obesity-Drug MakerVIVUS struggled in 2013. To compete with Arena Pharmaceuticals and Orexigen in 2014, the biotech needs a marketing partner.
Dec 23, 2013 by Brian Orelli, PhDMannKind Corporation's Awesomely Imperfect 2013MannKind had a nice run-up, but there's potential for more if it can convince investors that Afrezza can compete with Novo Nordisk and Eli Lilly.
Dec 22, 2013 by Brian Orelli, PhDCould Marijuana Be the Next Big Diabetes Treatment?The drug seems to control insulin, but Merck, Novo Nordisk, Sanofi and the rest of the diabetes-drug makers don't have anything to worry about.
Dec 20, 2013 by Brian Orelli, PhDNot-So-Solid Data Might Be Good Enough for VertexVertex Pharmaceuticals data for Kalydeco in R117H cystic fibrosis patients isn't very clean, but the drug could still get used in patients currently taking drugs from Gilead Sciences and Novartis.
Dec 20, 2013 by Brian Orelli, PhDNo News Is Good News for AmarinAmarin jumps on news that the FDA will delay a decision on Vascepa until a decision on an appeal is heard. Unfortunately, Merck's and AbbVie's trial data still put a dark cloud over the decision.
Dec 20, 2013 by Brian Orelli, PhDChristmas Comes Early for AriadAriad's Iclusig is back on the market, but won't compete with Novartis' Gleevec and Bristol-Myers Squibb's Sprycel.
Dec 19, 2013 by Brian Orelli, PhDDiabetes Partners Going Their Separate WaysBristol-Myers Squibb sells its part of the diabetes JV to AstraZeneca. The big loser could be MannKind, with one less potential partner.
Dec 18, 2013 by Brian Orelli, PhDObamacare Delay: Wimpy Would Love This OneInsurers, including Aetna UnitedHealth Group, and WellPoint, agree to accept payments after insurance kicks in.
Dec 18, 2013 by Brian Orelli, PhDHepatitis C Drug War Heats UpGilead Sciencs releases data that appears to show its drugs work better than AbbVie's drug combo, although both drugs work better than first-generation drugs from Vertex Pharmaceuticals and Merck.
Dec 17, 2013 by Brian Orelli, PhDPfizer Allows Teva to Sell Generic Viagra in Late 2017Setting a longstanding feud over the Pfizer's patents, Teva Pharmaceuticals will benefit from the earlier launch while paying Pfizer an undisclosed royalty.
Dec 11, 2013 by Brian Orelli, PhDEli Lilly Sees Generic Competition for Cymbalta (x6)Dr. Reddy's Laboratories, Teva Pharmaceuticals, and others gain FDA approval for generic versions of Eli Lilly's Cymbalta.
Dec 11, 2013 by Brian Orelli, PhDNew Obesity Drug Could Be Available in 6 MonthsOrexigen resubmits its marketing application for Contrave, setting up a battle for the bulge with VIVUS and Arena Pharmaceuticals.
